BofA lifts Gilead target to USD 172 as Gilead Sciences stock trades EUR 141.85
Published on 10/27/2026 at 12:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming results and pipeline
- Bank of America raised its Gilead target to USD 172.00 from USD 168.00 on October 20, 2026.
- Second-quarter revenue reached USD 7.80 billion, up 10.6 percent year over year.
- Gilead Sciences stock trades at EUR 141.85 at 12:04 p.m. CET at Lang & Schwarz on October 27, 2026, 0.05 percent above the Xetra close of October 26, 2026.
- Gilead will release third-quarter 2026 results after market close on October 29, 2026.
Gilead Sciences (ISIN US3755581036) was trading at EUR 141.85 at Lang & Schwarz on October 27, 2026 at 12:04 p.m. CET, up EUR 0.07 or 0.05 percent versus the Xetra close of October 26, 2026 at EUR 141.78. The immediate catalyst is Bank of America raising its Gilead target from USD 168.00 to USD 172.00 on October 20, 2026, as Investing.com reported.
Target rise meets a results date
The target increase followed positive phase 2 SWIFT data for oral emvistegrast in moderate-to-severe ulcerative colitis. Bank of America said the program could support a differentiated profile, while also identifying dose response, prior-treatment efficacy and durability through week 52 as points requiring further evidence.
Gilead's next scheduled disclosure is close. The company announced on October 15, 2026 that it will release third-quarter 2026 results after the market close on October 29, 2026, followed by a management webcast at 4:30 p.m. ET, according to Gilead Sciences.
What does the quarter mean for earnings?
The second-quarter comparison was mixed. Revenue reached USD 7.80 billion, up 10.6 percent from the same period a year earlier and above the USD 7.40 billion consensus estimate, while adjusted earnings per share came in at a loss of USD 6.75 against a forecast loss of USD 7.25, according to MarketBeat. The upcoming release will show whether product demand can offset the pressure visible in earnings.
Three dates frame the stock
On October 7, 2026, Truist Financial raised its target to USD 158.00 from USD 150.00. On October 20, 2026, Bank of America lifted its target to USD 172.00 from USD 168.00. On October 29, 2026, Gilead is scheduled to report third-quarter results and guidance.
Dates investors can mark
The next reporting date is October 29, 2026, and the webcast begins at 4:30 p.m. ET, according to the company release. The October 20 target update gives the market a current valuation reference before that report.
Stock stays near its yearly high
The euro quotation sits inside its 52-week range of EUR 98.96 to EUR 142.80 and is EUR 0.95 below the high. Market capitalization was EUR 174.5 billion as of October 27, 2026. The modest 0.05 percent premium to the Xetra close leaves the October 29 results as the next clearly dated test for the shares.
Gilead Sciences was trading at EUR 141.85 at Lang & Schwarz on October 27, 2026 at 12:04 p.m. CET, 0.05 percent above the Xetra close of October 26, 2026 at EUR 141.78. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 27, 2026, 12:04 p.m. CET): EUR 141.85
- Change versus Xetra close: plus 0.05 percent
- Xetra close (October 26, 2026): EUR 141.78
- Market capitalization: EUR 174.5 billion (as of October 27, 2026)
- 52-week range: EUR 98.96-EUR 142.80 (as of October 27, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Market context: Market report S&P 500.
